Preclinical and clinical data for more informed and faster drug development decisions

Successful drug development requires anticipating safety and regulatory issues as early as possible. To preclude drug approval challenges, preclinical safety assessment and clinical development teams require tools that enable data-driven drug discovery and development.

How PharmaPendium helps
PharmaPendium provides comparative regulatory-based evidence in a single translational database for better-informed risk-benefit analyses and drug candidate assessments. Users can leverage comparative information (drugs, drug classes, targets) to anticipate the best drug-development strategy.

Drug Discovery & Development - Reaxys | Elsevier

It provides searchable FDA and EMA regulatory documents, Adverse Events Reports and FDA Advisory Committee meetings, along with unique FAERs search capabilities and extracted pharmacokinetic, efficacy, safety and metabolising enzyme and transporter data. Pharmapendium helps users:

  • Identify and assess potential drug-drug interactions to define risk mitigation strategies
  • Improve the speed and success of regulatory submissions
  • Validate the best animal model to use and predict how results translate to the clinic

Ready to take the next step?
Contact us

  • Make better-informed decisions on which drugs have the best potential to succeed in clinical development
  • Avert potential safety and efficacy risks in clinical studies

Reaxys Customer Story | Elsevier

Featured customer story

Chris Penland, Senior Expert Modeller at Novartis, uses PharmaPendium to search for health authority review materials, labelling packages, adverse events and pharmacokinetic data.

Read the customer story (PDF, 783kb)

Read all PharmaPendium customer stories


How PharmaPendium works

PharmaPendium provides Drug Safety and FAERs data, along with dedicated data modules that provide insights and information on the critical focused areas of drug development, drug safety, ADME and drug-drug interactions.

Download the PharmaPendium Fact Sheet (PDF, 883kb)

Efficacy Module


Optimize drug candidate selection and mitigate the risk of sub-optimal clinical trial study designs with deeply enriched, comparative efficacy data extracted from FDA and EMA drug approval documents.

Download the Efficacy Module Fact Sheet (PDF, 2.6mb)

Pharmacokinetics Module


Drive successful regulatory approval strategies by analyzing drug candidates' pharmacokinetic properties within the context of the complete landscape of approved drugs.


Download the Pharmacokinetics Module Fact Sheet (PDF, 854kb)

Metabolizing Enzyme and
Transporter Proteins Module

Uncover potential drug-drug interactions with access to a unique source of searchable preclinical and clinical metabolizing enzymes and transporter data.


Download the Metabolizing Enzyme and Transporter Proteins Fact Sheet (PDF, 1.2mb)


PharmaPendium efficacy module for translational and clinical research

Mitigate the Risk of Efficacy-Related Clinical Failure - PharmaPendium | Elsevier

As clinical trials become more complex and costly, optimized study designs that take drug candidate efficacy and efficacy precedents into account are an essential part of risk mitigation. Learn how the PharmaPendium Efficacy Module can help you mitigate the risk of efficacy-related clinical failure.

Read more about PharmaPendium's Efficacy Module


Ideas and insights for industry professionals

Real Stories. Real Science. Real Time.

Real Stories. Real Science. Real Time. - R&D Solutions | Elsevier

Visit the Hive to explore how biotech and pharma start-ups are using Elsevier R&D solutions to solve for early-stage drug discovery and development.

Learn more about the Hive

Antibody-drug conjugates


Antibody-drug conjugates - R&D Solutions | Elsevier

Antibody-drug conjugates, or ADCs, are a class of exciting new therapeutics that utilize the patient’s own immune system, with the antibody delivering the drug right to the disease site.

Read the white paper

The Era of Immunotherapeutics

The Era of Immunotherapeutics - R&D Solutions | Elsevier

By boosting anti-cancer response using a patient’s own immune system, immunotherapeutics are showing incredible promise in offering more effective treatments with fewer side effects for cancer patients.

Read the white paper


Learn more about Elsevier's R&D Solutions for Drug Discovery & Development

Realize the potential of data-driven drug discovery and development with solutions that help you increase research efficiency and ensure a thriving R&D pipeline.
Learn more about Drug Discovery & Development solutions